2026-04-07 LIDR Meeting Notes
Date
Apr 7, 2026
Attendees
Bolded names indicates attendance
Name | Organization |
|---|---|
Hung Luu | Children’s |
Riki Merrick | Vernetzt, APHL |
Andrea Pitkus | University of Wisconsin |
Pam Banning | 3M - Solventum |
Xavier Gansel | Biomerieux |
Amy McCormick | Epic |
Dan Rutz - regrets | Epic |
Rob Rae | CAP |
Rob Hausam | Hausam Consulting |
Stan Huff | University of Utah |
Ed Heierman | Abbott / IICC |
Carmen Pugh - regrets | long term lab professional |
Laurent Lardin | Biomerieux |
Ralf Herzog | Roche |
Christina Gallegos | APHL |
Manjula Dharmawardhana | CDC |
Jim Harrison | CAP |
Follow up on UDI representation | Adding Conclusion here: UDI Background Summary from last week: Goal is to focus on interfaced data UDIs are linked to the result values Full UDI needed for end users No need to have the types identified - if you can look up by UDI, just do that consider software as a medical device (specific algorithms) FYI = Answers to the questions around UDI:
I am not sure even AI could make sense of this one yet....but it is worth a try if someone has time to create some prompts.
|
Vison 2030 work considerations | SHIELD focus should be for the top lab tests, even if some are not part of PT - see here for current thoughts:https://docs.google.com/spreadsheets/d/1zpbjDmWgA-RQW8fJdTe5kHZG6LwAAVzqeCHxhCNXR4g/edit?usp=sharing Discussion today: Reviewed the googlesheet - goal is to pick a few of the most common tests, identify all available tests and collect LIVD from vendors (or collect LOINCs and create LIVD content), check for any LOINC and SCT gaps for these - then we can include this as specific milestones in the vision 2030 letter and come up with phased goals for implementation googlesheet has a few tabs:
Note that there are some calculations that are not in the CAP catalog, that we probably should include also for some tests, PT results get reported differently than for clinical care - example is for blood cell differentiations those are done in PT in a web-portal, so not in LIS/LIMS Stan also did a review identifying which of the top LOINCs could cover about 80% of test volume - he will look for that Can look up what tests are available by analyte as 510k approved: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCLIA/Search.cfm?sAN=0 Decide to focus on these panels to start: BMP CBC Lipid SARS-CoV-2 = already have LIVD file = https://www.cdc.gov/laboratory-systems/php/livd-test-codemapping/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcsels%2Fdls%2Flivd-codes.html need to check what is missing from it and add it Worksteps for the common tests LIVD file work: Identify the panel we want to use to pick analytes for each analyte:
|
LIDR Patterns |
|
Action Item Follow up |
|
Next call | Going to twice a month for meetings to allow for homework time, so next call Tuesday Apr 21, 2026 9 - 10 AM ET |
Chat
Andrea Pitkus 9:21 AM
https://documents.cap.org/documents/2026-Surveys-Catalog.pdf?_gl=1*1udcyrz*_ga*MTE3NTgzOTAxNy4xNzUwNzkxNDY3*_ga_97ZFJSQQ0X*czE3NzM5Mzk2NTAkbzQyJGcxJHQxNzczOTM5NjgyJGoyOCRsMCRoMA..
CAP 2026 product catalog
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCLIA/results.cfm?start_search=1&Test_System_Name=&Qualifier=&Analyte_Name=Hemoglobin&Document_Number=&Clia_Analyte_Specialty=&Clia_Complexity=&Effective_Date_FROM=&Effective_Date_TO=&Exempt_510k=&SortColumn=ded&PAGENUM=500
FDA listing of 500+ hgb assays
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCLIA/search.cfm